Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Centro di Riferimento Oncologico - Aviano | OTHER |
| IRCCS Burlo Garofolo | OTHER |
Not provided
Not provided
Not provided
Not provided
The primary goal of this observational study is to evaluate the feasibility of implementing a multidisciplinary approach based on pharmacogenetics, TDM (Therapeutic Drug Monitoring) and MedReview into the clinical practice in order to optimize the appropriateness of drugs prescription and to minimise the risk of Adverse Drug Reactions (ADRs) in adult cancer patients and in pediatric patients affected by chronic inflammatory diseases. This approach of active pharmacovigilance will also allow a better definition of the causality assessment of ADRs through the direct implementation of data quality in the reporting forms. The study may therefore constitute an example of an approach for both the prevention of ADRs and the optimization of drug use, and for the integration of pharmacogenetics, TDM, and the MedReview data into the National Pharmacovigilance Reports for an improved and innovative evaluation of adverse events, aiming at the implementation of this approach in the regional context.
Primary aim of the study:
To implement the use of pharmacogenetics, TDM, and MedReview at the regional level supporting their utility through an observational approach to assess the effects of these innovative methods, already active in IRCCS, for the optimization of appropriate drug use and minimization of ADR risk in adult and pediatric oncology patients, as well as pediatric patients with chronic inflammatory diseases. Specifically, the aim is to evaluate the incidence of ADRs in patients treated based on pharmacogenetics, TDM, and MedReview compared to historical cases treated according to the standard of care before the implementation of the proposed innovative methodologies.
Secondary aims of the study:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Adult patients | Adult cancer patients |
| |
| Pediatric patients | Pediatric patients with chronic inflammatory diseases |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pharmacogenetics, TDM and MedReview | Other | Patients will undergo pharmacogenetics, TDM and MedReview analyses according to the study protocol |
|
| Measure | Description | Time Frame |
|---|---|---|
| Patients treated with study drugs tested with pharmacogenetic and TDM analysis | Percentage of patients treated with study drugs tested with pharmacogenetic and TDM analysis on total patients treated | Up to 2 years |
| MedReview reports | Number of MedReview reports | Up to 2 years |
| ADRs in patients treated on the basis of pharmacogenetics, TDM and MedReview | Incidence of ADRs in the study cohorts | Up to 2 years |
| Comparison of ADRs in patients treated on the basis of pharmacogenetics, TDM and MedReview and retrospective data | Difference in incidence of ADRs in the prospective cohort will be tested against historical data with binomial test | Up to 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Integration of pharmacogenetics, TDM and MedReview information in the existing tool for the evaluation of "Causality assessment" between ADR and specific drug | Change of Causality Assessment. The change is evaluated as the number of "definite" and "probable" associations between ADRs and suspected drugs compared with historical data | Up to 2 years |
Not provided
Inclusion Criteria:
Patients who are candidates for therapy with:
Not provided
Not provided
Not provided
Not provided
Patients who are candidates for therapy with: Abemaciclib, Palbociclib, Ribociclib, Letrozole, Tamoxifen, Olaparib, Infliximab, Cyclophosphamide, Methotrexate, Irinotecan, Capecitabine, 5-Fluorouracil, Noraparib, Adalimumab, Imatinib, Regorafenib, Lenvatinib, Sorafenib, Sunitinib, Rucaparib, 6-MP/ Azathioprine
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Erika Cecchin | Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centro di Riferimento Oncologico di Aviano (CRO) | Aviano | Pordenone | 33081 | Italy | ||
| IRCCS materno infantile Burlo Garofolo di Trieste |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Proposal for updating the pharmacovigilance reporting forms including Pharmacogenetics, TDM and MedReview information in the National Network of Pharmacovigilance | Frequencies of new reports sent to the National Pharmacovigilance Network, including pharmacogenetics, TDM, and drug interaction data | Up to 2 years |
| European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 v3 | The EORTC QLG Core Questionnaire (EORTC QLQ-C30) is a 30-item instrument designed to measure quality of life in all cancer patients. The possible answers to the questionnaire range from a minimum value ("not at all") to a maximum value ("very much"). Higher values indicate a worse quality of life. Mean and standard deviation of scores at EORTC QLQ-C30 v3 questionnaire will be evaluated. | Up to 2 years |
| Costs of ADRs management | Median and interquartile range of costs | Up to 2 years |
| Concordance between plasmatic concentration measured with conventional methods and with new methods such as Dried Blood Spot (DBS) | Lin's correlation coefficient between plasmatic concentration and DBS estimation | Up to 2 years |
| Correlation between pharmacogenetic profile and drug exposure (TDM) | Difference in drug exposure measured as Cmin for different pharmacogenetic profiles | Up to 2 years |
| Correlation between ADRs, TDM and pharmacogenetics analyses | Frequencies of ADRs in different subgroups of patients defined by TDM and pharmacogenetic profiles | Up to 2 years |
| Correlation between ADRs, TDM and pharmacogenetics analyses | Frequencies of severe ADRs in different subgroups of patients defined by TDM and pharmacogenetic profiles | Up to 2 years |
| Trieste |
| Trieste |
| 34137 |
| Italy |
| ID | Term |
|---|---|
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| ID | Term |
|---|---|
| D064419 | Chemically-Induced Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000071185 | Pharmacogenomic Testing |
| ID | Term |
|---|---|
| D005820 | Genetic Testing |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D008919 | Investigative Techniques |
| D005821 | Genetic Techniques |
| D033142 | Genetic Services |
| D006296 | Health Services |
| D005159 | Health Care Facilities Workforce and Services |
| D003954 | Diagnostic Services |
| D011314 | Preventive Health Services |
Not provided
Not provided